To evaluate the clinical efficacy and safety of Bailing capsule in the treatment of patients with chronic kidney disease stage 2-4 (CKD stage 2-4)
- Conditions
- Stage 2 through 4 chronic kidney disease
- Registration Number
- ITMCTR2024000026
- Lead Sponsor
- Zhongda Hospital affiliated to Southeast University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- Not specified
1. The initial diagnosis met the western diagnostic criteria for chronic kidney disease: chronic kidney structure and dysfunction or decreased glomerular filtration rate (GFR) caused by various reasons for more than 3 months; Renal injury included: (1) proteinuria: urinary albumin excretion rate (UAER) = 30 mg/24 h; Urinary albumin-to-creatinine ratio (ACR) = 30 mg/g (=3 mg/mmol), (2) abnormal urinary sediment, (3) electrolyte and other abnormalities caused by renal tubular dysfunction, (4) histological abnormalities, (5) abnormal imaging examination, (5) abnormal renal function. (6) History of renal transplantation.
2. CKD stage 2 (GFR=60 ml/min/1.73 m2, and GFR < 90ml/min/1.73 m2) or CKD stage 3 (GFR=30 ml/min/1.73 m2, GFR=30 ml/min/1.73 m2; GFR < 60ml/min/1.73 m2) or CKD stage 4 (GFR=15 ml/min/1.73 m2 and GFR < 30ml/min/1.73 m2);
(3) The first visit time is 2017-1-1 to 2022-6-30, and the age is 18 years old and above.
1. Patients who used other Chinese patent medicine of cordyceps sinensis from 2017-1-1 to 2022-6-30;
(2) patients who underwent dialysis less than 3 months after the first diagnosis of CKD2-4 or CKD
Patients with extended;
3. Diagnose patients not associated with chronic kidney disease or chronic renal insufficiency.
4. Inability to judge the efficacy or incomplete data affecting the efficacy or safety judgment.
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to first occurrence of the composite end point;
- Secondary Outcome Measures
Name Time Method The usage of Bailing capsule during the study period, including the dosage and duration, etc;The proportion of patients with a =30% decrease in the urinary albumin-to-creatinine ratio (UACR);The complication rate of chronic kidney disease;All-cause mortality;